Even in the 21st century, prostate cancer remains the second leading cause of cancer-related death for men. Since a normal prostate gland has a high Zn content and there are huge differences in Zn content between healthy and malignant prostate cancer cells, mobile zinc can be used as a biomarker for prostate cancer prediction. A highly efficient surface enhanced Raman spectroscopy (SERS) probe using a p-(imidazole)azo)benzenethiol attached gold nanoparticle as a Raman reporter, which has the capability to identify prostate cancer cells based on Zn sensing, has been designed. A facile synthesis, characterization and evaluation of a Zn sensing Raman probe are described. Reported data indicate that after binding with Zn , Raman reporter attached to a gold nanoparticle forms an assembly structure, which allows selective detection of Zn even at 100 ppt concentration. Theoretical full-wave finite-difference time-domain (FDTD) simulations have been used to understand the enhancement of the SERS signal. The SERS probe is highly promising for in vivo sensing of cancer, where near-IR light can be easily used to avoid tissue autofluorescence and to enhance tissue penetration depth. Reported data show that the SERS probe can distinguish metastatic cancer cells from normal prostate cells very easily with a sensitivity as low as 5 cancer cells mL . The probe can be used as a chemical toolkit for determining mobile Zn concentrations in biological samples.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399513PMC
http://dx.doi.org/10.1002/asia.201601685DOI Listing

Publication Analysis

Top Keywords

prostate cancer
20
sers probe
16
cancer cells
16
selective detection
8
prostate
8
malignant prostate
8
cancer
8
normal prostate
8
attached gold
8
gold nanoparticle
8

Similar Publications

Background: Cancer requires interdisciplinary intersectoral care. The Care Coordination Instrument (CCI) captures patients' perspectives on cancer care coordination. We aimed to translate, adapt, and validate the CCI for Germany (CCI German version).

View Article and Find Full Text PDF

Randomized controlled trials (RCTs) evaluating anti-cancer agents often lack generalizability to real-world oncology patients. Although restrictive eligibility criteria contribute to this issue, the role of selection bias related to prognostic risk remains unclear. In this study, we developed TrialTranslator, a framework designed to systematically evaluate the generalizability of RCTs for oncology therapies.

View Article and Find Full Text PDF

To investigate the potential of an MRI-based radiomic model in distinguishing malignant prostate cancer (PCa) nodules from benign prostatic hyperplasia (BPH)-, as well as determining the incremental value of radiomic features to clinical variables, such as prostate-specific antigen (PSA) level and Prostate Imaging Reporting and Data System (PI-RADS) score. A restrospective analysis was performed on a total of 251 patients (training cohort, n = 119; internal validation cohort, n = 52; and external validation cohort, n = 80) with prostatic nodules who underwent biparametric MRI at two hospitals between January 2018 and December 2020. A total of 1130 radiomic features were extracted from each MRI sequence, including shape-based features, gray-level histogram-based features, texture features, and wavelet features.

View Article and Find Full Text PDF

Alexithymia, a cognitive and emotional deficit characterized by difficulty in expressing emotions and identifying feelings, poses significant challenges in healthcare settings. Developing a reliable and valid tool to measure alexithymia in post-prostatectomy patients would not only aid healthcare professionals in identifying at-risk individuals but also facilitate early intervention and targeted support. This study aimed to translate the Brief Form of the Normative Male Alexithymia Scale (NMAS-BF) into Simplified Chinese, evaluate the reliability and validity of the Chinese version, and explore its influencing factors.

View Article and Find Full Text PDF

Tumor-intrinsic regulators of the immune-cold microenvironment of prostate cancer.

Trends Endocrinol Metab

January 2025

Department of Urology, Emory University School of Medicine, Atlanta, GA, USA; Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, USA; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. Electronic address:

Prostate cancer (PC) is a notoriously immune-cold tumor in that it often lacks substantial infiltration by antitumor immune cells, and in advanced diseases such as neuroendocrine PC, it could be devoid of immune cells. A majority of PC patients thus have, unfortunately, been unable to benefit from recent advances in immunotherapies. What causes this immunosuppressive microenvironment around PC? In this review, we discuss various genetic and epigenetic regulators intrinsic to prostate tumor cells that could have profound effects on the tumor microenvironment, thus contributing to this immune-cold status.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!